The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Vertex has been developing inhibitors to the NaV1.8 sodium channel for many years and previously abandoned other candidates because they were not selective enough for the target and inhibited ...

indicating the potential of an oral APOL1 inhibitor to decrease proteinuria in AMKD patients. Vertex chief medical officer and Global Medicines Development and Medical Affairs executive vice ...

Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548). BOSTON & SEATTLE, April 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune ...

The other near-term shot at blockbuster revenues is Vertex's pain therapy, Suzetrigine, a "novel, highly selective Nav1.8 pain signal inhibitor" which Vertex says: has the potential to provide a ...

led by povetacicept and AbbVie-partnered dual CD28 and ICOS inhibitor acazicolcept, which is in a phase 2 lupus trial, with results due later this year. Vertex has built its business on genetic ...

A Vertex spokesperson told Barron’s that both ... The most recent example, nerve growth factor inhibitors, were plagued with ...

Data from a late-stage trial of the most advanced of a new class of drugs targeting the hepatitis C virus protease fuel hopes for major improvements in treatment outcomes. In May this year, Vertex ...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- Encouraging Results Support ...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Merck & Co., Inc. (NYSE ...

And we're really excited to have the Vertex IR team with us ... is a selective NaV1.8 channel inhibitor. So, we're stopping pain where it occurs in the peripheral neurons and because of that we don't ...